Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial).

[1]  E. Schaefer,et al.  Abstract 20007: Effects of Eicosapentaenoic Acid, Docosahexaenoic Acid, and Olive Oil on Cardiovascular Disease Risk Factors , 2010 .

[2]  M. Binns,et al.  Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid dose-dependently reduce fasting serum triglycerides. , 2010, Nutrition reviews.

[3]  J. Mckenney,et al.  Effects of prescription omega-3-acid ethyl esters on non--high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin. , 2010, Mayo Clinic proceedings.

[4]  J. Danesh,et al.  Major lipids, apolipoproteins, and risk of vascular disease. , 2009, JAMA.

[5]  Robert Dufour,et al.  Canadian Cardiovascular Society / Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations , 2009 .

[6]  P. McCullough.  Darapladib and atherosclerotic plaque: Should lipoprotein-associated phospholipase A2 be a therapeutic target? , 2009, Current atherosclerosis reports.

[7]  S. Egert,et al.  Dietary alpha-linolenic acid, EPA, and DHA have differential effects on LDL fatty acid composition but similar effects on serum lipid profiles in normolipidemic humans. , 2009, The Journal of nutrition.

[8]  M. Corson,et al.  Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. , 2008, The American journal of cardiology.

[9]  Curt D. Furberg,et al.  Lipoprotein Management in Patients With Cardiometabolic Risk , 2008, Diabetes Care.

[10]  A. Tighe,et al.  Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications , 2008, Expert review of cardiovascular therapy.

[11]  C. Ballantyne,et al.  Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. , 2007, Clinical therapeutics.

[12]  Y. Matsuzawa,et al.  Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis , 2007, The Lancet.

[13]  J. Lau,et al.  Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. , 2006, Atherosclerosis.

[14]  A. Jaffe,et al.  Lipoprotein-Associated Phospholipase A2 and Prognosis After Myocardial Infarction in the Community , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[15]  C. Meisinger,et al.  Lipoprotein-Associated Phospholipase A2 Adds to Risk Prediction of Incident Coronary Events by C-Reactive Protein in Apparently Healthy Middle-Aged Men From the General Population: Results From the 14-Year Follow-Up of a Large Cohort From Southern Germany , 2004, Circulation.

[16]  J. Cleeman,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[17]  W. Harris,et al.  Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance Published, JLR Papers in Press, December 1, 2002. DOI 10.1194/jlr.M200282-JLR200 , 2003, Journal of Lipid Research.

[18]  Albert Rabinovitch,et al.  The College of American Pathologists laboratory accreditation program , 2002 .

[19]  P. Nestel,et al.  The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans. , 2002, The American journal of clinical nutrition.

[20]  T. Kurabayashi,et al.  Eicosapentaenoic Acid Effect on Hyperlipidemia in Menopausal Japanese Women , 2000, Obstetrics and gynecology.

[21]  G. Watts,et al.  Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. , 2000, The American journal of clinical nutrition.

[22]  G. Franceschini,et al.  Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. , 2000, Atherosclerosis.

[23]  H. Nihei,et al.  Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. , 1999, Journal of the American Society of Nephrology : JASN.

[24]  A. Goldberg,et al.  Fenofibrate for the treatment of type IV and V hyperlipoproteinemias: a double-blind, placebo-controlled multicenter US study. , 1989, Clinical therapeutics.

[25]  S. J. Smith,et al.  The Centers for Disease Control-National Heart, Lung and Blood Institute Lipid Standardization Program. An approach to accurate and precise lipid measurements. , 1989, Clinics in laboratory medicine.

[26]  P. Kwiterovich.  The Johns Hopkins textbook of dyslipidemia , 2010 .

[27]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[28]  J. Albers,et al.  A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. , 1978, Journal of lipid research.